Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside.
暂无分享,去创建一个
J. Balzarini | S. Liekens | C. Mcguigan | Magdalena Ślusarczyk | J. Vande Voorde | Blanka Gonczy | Paola G. S. Murziani | C. Mcguigan*
[1] E. Gorovits,et al. Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. , 2010, Bioorganic & medicinal chemistry letters.
[2] J. Balzarini,et al. Improvement of purine and pyrimidine antimetabolite-based anticancer treatment by selective suppression of mycoplasma-encoded catabolic enzymes. , 2009, The Lancet. Oncology.
[3] W. Parker. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. , 2009, Chemical reviews.
[4] J. Balzarini,et al. The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: Implications for cancer therapy. , 2008, Biochemical pharmacology.
[5] M. Erion,et al. Prodrugs of phosphates and phosphonates. , 2008, Journal of medicinal chemistry.
[6] W. Lipscomb,et al. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes. , 2007, Journal of the American Chemical Society.
[7] William A. Lee,et al. Cathepsin A Is the Major Hydrolase Catalyzing the Intracellular Hydrolysis of the Antiretroviral Nucleotide Phosphonoamidate Prodrugs GS-7340 and GS-9131 , 2006, Antimicrobial Agents and Chemotherapy.
[8] M. Mason,et al. Novel potential anticancer naphthyl phosphoramidates of BVdU: separation of diastereoisomers and assignment of the absolute configuration of the phosphorus center. , 2006, Journal of medicinal chemistry.
[9] M. Mason,et al. Anti-cancer ProTides: tuning the activity of BVDU phosphoramidates related to thymectacin. , 2005, Bioorganic & medicinal chemistry.
[10] E. De Clercq,et al. Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. , 2005, Journal of medicinal chemistry.
[11] J. Balzarini,et al. Aryloxy phosphoramidate triesters as pro-tides. , 2004, Mini reviews in medicinal chemistry.
[12] P. Johnston,et al. 5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.
[13] R. Martino,et al. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. , 2002, The oncologist.
[14] R. Stroud,et al. Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. , 2001, Biochemical pharmacology.
[15] J. Grem. 5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development , 2000, Investigational New Drugs.
[16] N. Suzuki,et al. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. , 2000, International journal of oncology.
[17] E. De Clercq,et al. Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine. , 1999, Molecular pharmacology.
[18] E. De Clercq,et al. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. , 1999, Biochemical pharmacology.
[19] E. De Clercq,et al. Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[20] E. De Clercq,et al. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. , 1996, Journal of medicinal chemistry.
[21] E. De Clercq,et al. Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. , 1993, Journal of medicinal chemistry.
[22] Ensminger Wd,et al. Clinical pharmacology of hepatic arterial chemotherapy. , 1983 .
[23] E. Yagil,et al. Phosphorolysis of 5-Fluoro-2′-Deoxyuridine in Escherichia coli and Its Inhibition by Nucleosides , 1971, Journal of bacteriology.
[24] C. Heidelberger,et al. Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds , 1957, Nature.
[25] J. Homsi,et al. Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer. , 2006, Cancer control : journal of the Moffitt Cancer Center.